Managing and Reducing Cardiovascular Risk in Type 2 Diabetes Mellitus
Managing and Reducing Cardiovascular Risk In
Type 2 Diabetes Mellitus
INTRODUCTION
Diabetes mellitus is a metabolic disorder in which the body’s capacity to make use of glucose, fat and protein is disturbed due to insulin deficiency or insulin resistance.
It is a hormone secreted from pancreas that helps glucose from food to enter the body 's cells where it is transformed into energy required by muscles and tissues to function. Diabetes is caused either because the pancreas does not secrete adequate insulin, or because cells do not react to the insulin that is produced. Due to this reason, an individual with diabetes does not take up glucose appropriately and glucose continues circulating in the blood (hyperglycaemia) harming tissues over time. This damage leads to acute health complications. The classic symptoms of diabetes mellitus are, Polyuria ,Polydipsia ,Polyphagia ,lethargy and weight loss.
There are many causes for high blood glucose levels in the body and so a number of types of diabetes exist. Diabetes mellitus occur throughout the world. Based on the study conducted by IDF, the number of diabetics on earth stands at 365 million nearly 8.5% of the global population. It is more widespread in the more developed countries. The greatest raise in incidence is, however, expected to happen in Africa and Asia, where majority of the diabetes patients will most likely be found by 2030.
Diabetes mellitus is categorised into four broad groups: Type 1, Type 2, Gestational diabetes & "other specific types". Scientists in US have found a Type 3 diabetes, it is still continuing further study. Type 1 diabetes is absolute insulin deficiency usually affects children and young adults. Type 2 Diabetes is an insidious progressive disease that is often diagnosed late when complication are present. Dunning (2004) described it as a long term complication with neuropathy, cardiovascular disease and retinopathy.
It is a universal metabolic disorder affecting
Type 2 Diabetes Mellitus
INTRODUCTION
Diabetes mellitus is a metabolic disorder in which the body’s capacity to make use of glucose, fat and protein is disturbed due to insulin deficiency or insulin resistance.
It is a hormone secreted from pancreas that helps glucose from food to enter the body 's cells where it is transformed into energy required by muscles and tissues to function. Diabetes is caused either because the pancreas does not secrete adequate insulin, or because cells do not react to the insulin that is produced. Due to this reason, an individual with diabetes does not take up glucose appropriately and glucose continues circulating in the blood (hyperglycaemia) harming tissues over time. This damage leads to acute health complications. The classic symptoms of diabetes mellitus are, Polyuria ,Polydipsia ,Polyphagia ,lethargy and weight loss.
There are many causes for high blood glucose levels in the body and so a number of types of diabetes exist. Diabetes mellitus occur throughout the world. Based on the study conducted by IDF, the number of diabetics on earth stands at 365 million nearly 8.5% of the global population. It is more widespread in the more developed countries. The greatest raise in incidence is, however, expected to happen in Africa and Asia, where majority of the diabetes patients will most likely be found by 2030.
Diabetes mellitus is categorised into four broad groups: Type 1, Type 2, Gestational diabetes & "other specific types". Scientists in US have found a Type 3 diabetes, it is still continuing further study. Type 1 diabetes is absolute insulin deficiency usually affects children and young adults. Type 2 Diabetes is an insidious progressive disease that is often diagnosed late when complication are present. Dunning (2004) described it as a long term complication with neuropathy, cardiovascular disease and retinopathy.
It is a universal metabolic disorder affecting
References: Bakris GL, Gaxiola E, Messerli FH et al. (2004). Clinical outcomes in the diabetes cohort of the International Verapamil SR-Trandolapril Study Barnett, Tony; Kumar, Sudhesh (2009). Obesity and Diabetes (2nd Edition). Hoboken, NJ, USA: Wiley Best J, Colagiuri S, Malouf N, et al.(2002) Evidence based guidelines for type 2 Butler RN.( 1997) Population aging and health. BMJ;315:1082– 4. Coutinho M, Gerstein HC, Wang Y, Yusuf S (1999). The relationship between glucose and incident cardiovascular events Deurenberg, P., Yap, M. and van Staveren, W.A. (1998) Body mass index and percent body fat: a meta analysis among different ethnic groups Related Metabolic Disorders, (12), 1164– 71. Fisher, Miles (Editor); McMurray, John J. (2008). Diabetic Cardiology. of Clinical Nutrition, 1111– 18. 9. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Kaakso M (1998). Mortality from coronary heart disease in subjects with type 2 diabetes and in non diabetic subjects with and without Harris M, Zimmet P. (1997) Classification of diabetes mellitus and other categories of glucose intolerance Knowler, W.C., Pettitt, D.J., Savage, P.J. and Bennett, P.H. (1981) Diabetes incidence in Pima Indians: contributions of obesity and parental diabetes Kunugi T (1989) Women and population aging. Asia Pac Pop J ;4:75– 9. Marso, Steven (2003); Awad, Ahmed; Bhatt, Deepak. Handbook of Diabetes Mellitus and Cardiovascular Disease.London, GBR: Remedica. Must, A. (1992) Heart Protection Study of cholesterol lowering with Simvastatin in 20536 highrisk individuals England Journal of Medicine, (19), 1350– 5. Modan M, Halkin H, Almog S et al. (1985). Hyperinsulinemia: a link between hypertension, obesity and glucose intolerance Reaven GM (1999). Intensive blood pressure/glucose control in type 2 diabetes: why is it so difficult to decrease coronary heart disease? Journal of Human Hypertension 13: S19– 23. Scheen AJ (2004). Prevention of type 2 diabetes mellitus through inhibition of the reninangiotensin system Sowers JR, Haffner S (2002). Treatment of cardiovascular and renal risk factors in the diabetic hypertensive Staessen JA, Fagard R, Thijs L et al. (1997). Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension Susan Laing, Fisher, Miles McMurray, John J. (2008) Diabetic Cardiology.Chichester, GBR: Wiley. UK Prospective Diabetes Study Group (1998b). Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS UKPDS (2002)Intensive diabetes management: implications of the DCCT and UKPDS. Diabetes Educ. 2002 Sep-Oct;28(5):735-40. Watkins, Peter J.; Amiel, Stephanie A.; Howell, Simon L. (2008) Diabetes and Its Management.Chichester, GBR: Wiley.